GlassScriptPhysician profile
Robyn T Domsic
NPI 1790887966
$27,792.86
in general payments reported to CMS, 2019-2025
10 companies · $4,885 in 2025
The $4,885 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2021: $1,350 · 2022: $473 · 2023: $1,323 · 2024: $19K · 2025: $4,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $1,376 · Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,950.00 |
| Travel and Lodging | $1,375.71 |
| Food and Beverage | $366.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,429.20 | 2022-2024 | Saphnelo |
| Astrazeneca Uk Limited | $3,442.89 | 2023-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,595.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,592.50 | 2025 | |
| Csl Behring | $1,350.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $382.50 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Domsic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.